ATLANTA, GA--(Marketwired - Jan 9, 2015) - NeuroLaunch, the world's first startup accelerator program for neuroscience companies, has announced the program for its first Investor Demo Day on February 3, 2015. Investor Demo Day is a targeted investor showcase for the six startups completing the NeuroLaunch accelerator program, and will also feature approximately 20 poster presentations from top neuro-startups from around the world, as well as panels with thought leaders on "Investment Horizons in Neuroscience" and "The Future of Neuro-Wearables."
NeuroLaunch Investor Demo Day (Fall 2014 Cohort)
February 3, 2015, 1:00 PM-5:00 PM, cocktail reception following
Atlanta Tech Village, 3423 Piedmont Road NE, Atlanta, GA 30305
Capacity for Investor Demo Day is very limited; early registration is recommended. Early bird pricing, with a discount of $200, is available until January 15. For special investor or media pricing, please contact NeuroLaunch.
The NeuroLaunch portfolio companies being featured include:
- A neuro-wearable device platform for tracking and gamification of human infant brain development.
- A next-generation neuro-endovascular device employing novel technology to improve patient outcomes after acute ischemic stroke.
- An algorithmic platform enabling personalized genomics to treat epilepsy and other disorders.
- The future of cloud-based, three-dimensional neuroimaging for research and neurosurgical planning.
- A comprehensive system for radically streamlining clinical trials recruitment for neuro and other markets.
- Mobile-friendly peripherals for vital signs monitoring and neuroscience-based gamification of prevention strategies for stroke and other diseases.
"The portfolio companies in this cohort of NeuroLaunch represent some of the most promising neuro-startups we have identified from around the world," said Christopher Klaus, NeuroLaunch co-founder and serial entrepreneur.
These companies were selected from over 50 applications worldwide to join the first cohort of NeuroLaunch in Fall 2014. NeuroLaunch companies are given access to seed funding, world-class mentors, a 90-day tailored curriculum for business model validation, strategic partnerships and direct introductions to investors. Half of these companies came to NeuroLaunch from the Southeastern U.S.; the remainder hailed from Boston, New Haven (Connecticut), and Barcelona (Spain).
"NeuroLaunch marks a new era of joining startup culture with neuroscience in order to change the world," said Dr. Jordan Amadio, NeuroLaunch co-founder and resident physician in neurosurgery at Emory University. "We have introduced a novel method for accelerating innovations related to the brain and nervous system."
Amidst the growing number of successful startup accelerators around the globe, NeuroLaunch is unique for providing a curriculum, environment and roster of mentors customized for neuroscience-related companies. Its mission is to build a long-term community of stakeholders around neuro-innovation. Learn more about NeuroLaunch at: www.NeuroLaunch.com; Twitter @NeuroLaunch; Facebook.com/NeuroLaunch.